Get the Stockscreener App
10.44
3.06%
-0.33
Pharming Group Nv Adr stock is traded at $10.44, with a volume of 31,712.
It is down -3.06% in the last 24 hours and down -8.90% over the past month.
Pharming Group is a biotechnology company focused on developing and commercializing therapies for rare and ultra-rare diseases, particularly immunological and genetic conditions with high unmet need. It operates as an integrated company with capabilities across clinical development, manufacturing, regulatory affairs, and commercialization, supported by scientific and operational expertise. It leverages its efficient infrastructure to expand its pipeline and improve patient access to treatment. The Company operates in the United States, Europe, and the rest of the world, with the United States contributing the majority of its revenue.
See More
Previous Close:
$10.77
Open:
$10.59
24h Volume:
31,712
Relative Volume:
1.60
Market Cap:
$738.92M
Revenue:
$370.44M
Net Income/Loss:
$12.19M
P/E Ratio:
60.59
EPS:
0.1723
Net Cash Flow:
$50.74M
1W Performance:
-3.15%
1M Performance:
-8.90%
6M Performance:
-34.63%
1Y Performance:
-29.08%
1-Day Range:
$10.36
$10.64
1-Week Range:
$10.36
$11.50
52-Week Range:
$9.62
$21.34
Pharming Group Nv Adr Stock (PHAR) Company Profile
Compare PHAR vs VRTX, REGN, MRNA, ARGX, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PHAR
Pharming Group Nv Adr
|
10.44 | 738.92M | 370.44M | 12.19M | 50.74M | 0.1723 |
VRTX
Vertex Pharmaceuticals Inc
|
522.38 | 132.40B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
796.02 | 81.95B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
194.82 | 77.78B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
962.22 | 60.20B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
199.86 | 42.84B | 742.00K | -1.37B | -1.07B | -7.0731 |
Pharming Group Nv Adr Stock (PHAR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-10-26 | Initiated | Canaccord Genuity | Buy |
| Dec-09-24 | Initiated | Jefferies | Buy |
Pharming Group Nv Adr Stock (PHAR) Latest News
Canaccord reiterates Pharming stock rating on positive trial data - Investing.com
Pharming Group N.V. (PHAR) Stock Price, News, Quote & History - Yahoo! Finance Canada
Pharming Group N.V. stock gains on MAC Alpha Capital’s new USD 29.84 million stake - AD HOC NEWS
Pharming Group (NASDAQ: PHAR) Secures FDA Nod for Pediatric Use of Joenja in APDS Treatment - Kalkine Media
Zai Lab LimitedADR Peer Comparison – Compare with Others - Value Research
Pharming Group N.V. ADS each representing 10 (PHAR) Peer Comparison – Compare with Others - Value Research
XORTX Therapeutics Inc. (XRTX) Peer Comparison – Compare with Others - Value Research
Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR) Short Interest Up 93.0% in July - MarketBeat
Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR) Given Average Rating of "Hold" by Brokerages - MarketBeat
Pharming Group (NASDAQ:PHAR) Shares Gap DownShould You Sell? - MarketBeat
Pharming Group (NASDAQ:PHAR) Sees Unusually-High Trading VolumeTime to Buy? - MarketBeat
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation int - The National Law Review
Bronstein, Gewirtz & Grossman, LLC Is Investigating Pharming Grou - The National Law Review
Pharming Group (PHAR) Securities Investigation NoticeLevi & Korsinsky - Sahm
Pharming Group (NASDAQ:PHAR) Shares Gap UpTime to Buy? - MarketBeat
Q3 EPS Estimates for Pharming Group Lowered by HC Wainwright - MarketBeat
Pharming Group (NASDAQ:PHAR) Shares Gap Down Following Weak Earnings - MarketBeat
Meta Posts Mixed Q2 Results, Joins Coursera, Qualcomm And Other Big Stocks Moving Lower In Thursday’s Pre - Benzinga
Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR) Short Interest Update - MarketBeat
Pharming Group NV Sponsored ADR Revenue Breakdown – DUS:PHG - TradingView
Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR) Given Average Rating of "Hold" by Analysts - MarketBeat
Pharming Q1 2026 slides: Joenja growth offset by RUCONEST decline - Investing.com
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Aga - The National Law Review
Bronstein, Gewirtz & Grossman, LLC Encourages Pharming Group N.V - The National Law Review
A2QLQY Forecast — Price Target — Prediction for 2027 - TradingView
Pharming Group NV Sponsored ADR Actuals & Estimates (NASDAQ:PHAR) - TradingView
PHG Forecast — Price Target — Prediction for 2027 - TradingView
DBV Technologies (DBVT) soars 5.3%: Is further upside left in the stock? - MSN
DBV Technologies (DBVT) Soars 5.3%: Is Further Upside Left in the Stock? - Yahoo Finance
Pharming earnings in focus: Can rare disease growth offset Q1 dip? - Investing.com
Form 6K Pharming Group NV For: 28 May By Investing.com - Investing.com South Africa
PHARPharming Group NV ADR Stock Price and Quote - Finviz
Pharming Group gears up to report Q4 earnings: What's in the cards? - MSN
PHARM.AS Stock Price, Quote & Chart | PHARMING GROUP NV (AMS:PHARM) - ChartMill
Earnings call transcript: Pharming Group Q1 2026 revenue declines amid RUCONEST challenges By Investing.com - Investing.com South Africa
Earnings call transcript: Pharming Group Q1 2026 revenue declines amid RUCONEST challenges - Investing.com India
Pharming Group Q1 Earnings Call Highlights - Barchart.com
Earnings call transcript: Pharming Group Q1 2026 sees stock drop amid revenue decline - Investing.com
Snap, Whirlpool, Nerdwallet And Other Big Stocks Moving Lower In Thursday's Pre-Market Session - Benzinga
Pharming Group reports first quarter 2026 financial results; on track for Joenja® U.S. pediatric label expansion and launches in Japan and Europe in 2026 - GlobeNewswire Inc.
Pharming earnings in focus: Can rare disease growth offset Q1 dip? By Investing.com - Investing.com South Africa
Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR) Sees Significant Decline in Short Interest - MarketBeat
Pharming Group Nv Adr Stock (PHAR) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.11%
1.87%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):